← Eichor
Study identifier: NCT06376916 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Condition: Tachycardia Atrial · Atrial Fibrillation · Atrial Flutter With Rapid Ventricular Response  ·  Sponsor: Wake Forest University Health Sciences

PhasePhase 3
Planned participants153
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.

This description comes directly from the study's public registry record.

Talk to the study team

Marc McDowell, PharmD  ·  (708) 684-1078  ·  marc.mcdowell@aah.org

Always discuss trial participation with your own doctor first.

Locations (1)

Advocate Christ Medical Center Emergency Department (ACMC ED)Oak Lawn, Illinois, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06376916